Rocket Pharmaceuticals Inc
RCKT2.510USD
-0.110-4.20%
收盘 05/30, 16:00（美东）报价延迟15分钟
267.95M总市值
亏损市盈率 TTM
关于 Rocket Pharmaceuticals Inc 公司
Rocket Pharmaceuticals, Inc. 是一家完全整合的后期生物技术公司。该公司正在推进一系列可持续的试验性基因疗法，旨在纠正复杂和罕见疾病的根本原因。其基于慢病毒 (LV) 载体的基因疗法针对血液病，包括针对范康尼贫血症（一种难以治疗的遗传病，会导致骨髓衰竭和潜在的癌症）、白细胞粘附缺陷-I (LAD-I)（一种严重的儿科遗传病，会导致反复发作且危及生命的感染，这些感染通常是致命的）和丙酮酸激酶缺陷 (PKD)（一种单基因红细胞疾病，导致红细胞破坏增加和轻度至危及生命的贫血）的后期项目。该公司还有两个临床阶段和一个临床前阶段的体内腺相关病毒 (AAV) 项目，包括针对 Danon 病、Plakophilin-2 致心律失常性心肌病和 BAG3 扩张型心肌病的项目。
公司简介
公司代码RCKT
公司名称Rocket Pharmaceuticals Inc
上市日期Feb 18, 2015
成立日期1999
CEODr. Gaurav D. Shah, M.D.
员工数量299
证券类型Ordinary Share
年结日Feb 18
公司地址9 Cedarbrook Drive
城市CRANBURY
上市交易所NASDAQ Global Market Consolidated
国家United States of America
邮编08512
电话16464409100
网址https://www.rocketpharma.com/
公司代码RCKT
上市日期Feb 18, 2015
成立日期1999
公司高管
名称
名称/职务
职务
持股
持股变动
Dr. Gaurav D. Shah, M.D.
Dr. Gaurav D. Shah, M.D.
Chief Executive Officer, Director
Chief Executive Officer, Director
1.21M
-0.48%
Dr. Gotham Makker, M.D.
Dr. Gotham Makker, M.D.
Independent Director
Independent Director
621.50K
-24.19%
Dr. Kinnari Patel, Pharm.D.
Dr. Kinnari Patel, Pharm.D.
President, Chief Operating Officer, Head of Research and Development
President, Chief Operating Officer, Head of Research and Development
513.63K
-0.42%
Mr. David P. Southwell
Mr. David P. Southwell
Independent Director
Independent Director
95.12K
-0.04%
Mr. John Militello, CPA
Mr. John Militello, CPA
Principal Accounting Officer, Vice President - Finance, Treasurer
Principal Accounting Officer, Vice President - Finance, Treasurer
57.84K
-1.72%
Mr. Aaron Ondrey
Mr. Aaron Ondrey
Chief Financial Officer, Principal Financial Officer
Chief Financial Officer, Principal Financial Officer
19.52K
-85.77%
Dr. Mikael G. Dolsten, M.D., Ph.D.
Dr. Mikael G. Dolsten, M.D., Ph.D.
Independent Director
Independent Director
14.22K
--
Mr. Pedro Granadillo
Mr. Pedro Granadillo
Independent Director
Independent Director
--
--
Ms. Sarbani Chaudhuri
Ms. Sarbani Chaudhuri
Chief Commercial and Medical Affairs Officer
Chief Commercial and Medical Affairs Officer
--
--
Dr. Jonathan Schwartz, M.D.
Dr. Jonathan Schwartz, M.D.
Chief Medical and Gene Therapy Officer
Chief Medical and Gene Therapy Officer
--
--
查看更多
名称
名称/职务
职务
持股
持股变动
Dr. Gaurav D. Shah, M.D.
Dr. Gaurav D. Shah, M.D.
Chief Executive Officer, Director
Chief Executive Officer, Director
1.21M
-0.48%
Dr. Gotham Makker, M.D.
Dr. Gotham Makker, M.D.
Independent Director
Independent Director
621.50K
-24.19%
Dr. Kinnari Patel, Pharm.D.
Dr. Kinnari Patel, Pharm.D.
President, Chief Operating Officer, Head of Research and Development
President, Chief Operating Officer, Head of Research and Development
513.63K
-0.42%
Mr. David P. Southwell
Mr. David P. Southwell
Independent Director
Independent Director
95.12K
-0.04%
Mr. John Militello, CPA
Mr. John Militello, CPA
Principal Accounting Officer, Vice President - Finance, Treasurer
Principal Accounting Officer, Vice President - Finance, Treasurer
57.84K
-1.72%
Mr. Aaron Ondrey
Mr. Aaron Ondrey
Chief Financial Officer, Principal Financial Officer
Chief Financial Officer, Principal Financial Officer
19.52K
-85.77%
收入明细
暂无数据
暂无数据
业务
地区
暂无数据
股东统计
更新时间: 5月17日 周六
更新时间: 5月17日 周六
持股股东
股东类型
持股股东
股东统计
占比
RTW Investments L.P.
16.42%
Wellington Management Company, LLP
6.64%
The Vanguard Group, Inc.
6.13%
BlackRock Institutional Trust Company, N.A.
5.71%
Maverick Capital, Ltd.
5.15%
Other
59.96%
持股股东
股东统计
占比
RTW Investments L.P.
16.42%
Wellington Management Company, LLP
6.64%
The Vanguard Group, Inc.
6.13%
BlackRock Institutional Trust Company, N.A.
5.71%
Maverick Capital, Ltd.
5.15%
Other
59.96%
股东类型
股东统计
占比
Investment Advisor/Hedge Fund
51.25%
Investment Advisor
20.03%
Hedge Fund
18.39%
Research Firm
4.48%
Individual Investor
2.60%
Bank and Trust
1.28%
Venture Capital
1.25%
Private Equity
1.13%
Pension Fund
0.17%
机构持股
更新时间: 3月4日 周二
更新时间: 3月4日 周二
报告期
机构数
持股数
持股占比
持股变动
2025Q1
469
117.28M
110.07%
+11.74M
2024Q4
469
115.66M
108.78%
+9.90M
2024Q3
442
99.39M
108.64%
-6.54M
2024Q2
434
97.04M
106.63%
-8.16M
2024Q1
431
98.54M
108.92%
-3.20M
2023Q4
427
94.76M
105.15%
-7.91M
2023Q3
413
94.89M
105.90%
+6.62M
2023Q2
408
81.61M
101.38%
-10.66M
2023Q1
419
83.81M
105.83%
-4.94M
2022Q4
433
80.68M
102.32%
-522.65K
查看更多
股东持股明细
名称
持股数
占比
持股变动
变动比例
公告日期
RTW Investments L.P.
17.69M
16.59%
--
--
Dec 31, 2024
Wellington Management Company, LLP
14.00M
13.13%
+2.75M
+24.49%
Dec 31, 2024
The Vanguard Group, Inc.
6.56M
6.16%
+1.04M
+18.84%
Dec 31, 2024
BlackRock Institutional Trust Company, N.A.
5.63M
5.28%
+524.20K
+10.26%
Dec 31, 2024
Maverick Capital, Ltd.
5.20M
4.88%
+1.08M
+26.23%
Dec 31, 2024
Westfield Capital Management Company, L.P.
4.71M
4.42%
+220.78K
+4.91%
Dec 31, 2024
State Street Global Advisors (US)
3.46M
3.24%
+356.06K
+11.48%
Dec 31, 2024
Suvretta Capital Management, LLC
2.57M
2.41%
+2.57M
--
Dec 31, 2024
Janus Henderson Investors
4.00M
3.76%
+2.11M
+111.03%
Dec 31, 2024
T. Rowe Price Associates, Inc.
3.09M
2.9%
-34.49K
-1.10%
Dec 31, 2024
查看更多
持股ETF
更新时间: 5月6日 周二
更新时间: 5月6日 周二
机构名称
占比
Virtus LifeSci Biotech Clinical Trials ETF
1.28%
Global X Genomics & Biotechnology ETF
1.18%
Harbor Health Care ETF
0.64%
Tema Cardiovascular and Metabolic ETF
0.35%
Main Thematic Innovation ETF
0.34%
SPDR S&P Biotech ETF
0.22%
Direxion Daily S&P Biotech Bull 3X Shares
0.14%
Federated Hermes MDT Small Cap Core ETF
0.12%
Franklin Genomic Advancements ETF
0.1%
ProShares Ultra Nasdaq Biotechnology
0.07%
查看更多
Virtus LifeSci Biotech Clinical Trials ETF
占比1.28%
Global X Genomics & Biotechnology ETF
占比1.18%
Harbor Health Care ETF
占比0.64%
Tema Cardiovascular and Metabolic ETF
占比0.35%
Main Thematic Innovation ETF
占比0.34%
SPDR S&P Biotech ETF
占比0.22%
Direxion Daily S&P Biotech Bull 3X Shares
占比0.14%
Federated Hermes MDT Small Cap Core ETF
占比0.12%
Franklin Genomic Advancements ETF
占比0.1%
ProShares Ultra Nasdaq Biotechnology
占比0.07%
分红派息
近5年累计派现
0.00
美元
公告日期
分红计划
股权登记日
现金发放日
除权除息日
暂无数据
拆合股
公告日期
类型
比率
暂无数据
公告日期
类型
比率
暂无数据
